Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: Impact on susceptibility and response to steroids

Gene

Volumn 530, Issue 2, 2013, Pages 201-207

  Youssef, Doaa M ^a   Attia, Tarek A ^a   El Shal, Amal S ^a   Abduelometty, Fawzya A ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Childhood nephrotic syndrome; MDR 1 gene polymorphisms; Steroid resistance

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; UREA; VALSPODAR;

ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; ONSET AGE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT RESPONSE; UREA BLOOD LEVEL;

ANOVA; CHILDHOOD NEPHROTIC SYNDROME; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; FSGS; GC; GLUCOCORTICOIDS; IDIOPATHIC NEPHROTIC SYNDROME; INS; MCN; MDR-1; MDR-1 GENE POLYMORPHISMS; MINIMAL CHANGE NEPHROPATHY; MULTIDRUG RESISTANCE-1; NEPHROTIC SYNDROME; NS; ONE WAY ANALYSIS OF VARIANCE; PCR-RFLP; POLYMERASE CHAIN REACTION RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SD; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; SR; SS; STEROID RESISTANCE; STEROID RESISTANT; STEROID SENSITIVE; STEROID-DEPENDENT;

AGE OF ONSET; ALLELES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; KIDNEY; MALE; NEPHROTIC SYNDROME; P-GLYCOPROTEIN; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STEROIDS;

EID: 84884531850     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.08.045     Document Type: Article

References (44)

1. Ahmad H., Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 2000, 84:342-346.
2. Ameyaw M.M., Regaterio F., Li T., Liu X., Tariq M., Mobarek A., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001, 11:217-221.
3. Anglicheau D., Verstuyft C., Laurent-Puig P., Becquemont L., Schlageter M.H., Cassinat B., et al. Association of the multidrug esistance-1 gene single nucleotide polymorphisms with the tacrolimus dose requirement in renal transplant recipients. J. Am. Soc. Nephrol. 2003, 14:1889-1896.
4. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 2001, 69:169-174.
6. Chemli J., Harbi A. Treatment of steroid-resistant idiopathic nephritic syndrome. Arch. Pediatr. 2009, 16(3):260-268.
7. Chiou Y.H., Wang L.Y., Wang T.H., Huang S.P. Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr. Nephrol. 2012, 27(9):1511-1517.
8. Choi H.J., Cho H.Y., Ro H., Lee S.H., Han K.H., Lee H., et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr. Nephrol. 2011, 26(11):1981-1988.
9. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:695-698.
10. Davutoglu M., Ece A., Bilic M., Dagli A. Steroid responsiveness of children with idiopathic nephrotic syndrome in the southeastern region of Turkey. Ren. Fail. 2007, 29(7):855-859.
11. Dilger K., Schwab M., Fromm M.F. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. 2004, 10:578-583.
12. Eichelbaum M., Fromm M.F., Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 2004, 26:180-185.
13. El Bakkali L., Rodrigues P.R., Kuik D.J., Ket J.C., Van Wijk J.A. Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatr. Nephrol. 2011, 26:1241-1246.
14. Fan Q., Xing Y., Ding J., Guan N., Zhang J. The relationship among nephrin, podocin, CD2AP and a-actinin might not be a true interaction in podocyte. Kidney Int. 2005, 69:1207-1215.
15. Gipson D.S., Massengill S.F., Yao L., Nagaraj S., Smoyer W.E., Mahan J.D., et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009, 124(2):747-757.
16. Gollapud S., Gupta S. Anti-P-glycoprotein antibody induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J. Clin. Immunol. 2001, 21:420-430.
17. Gumus-Akay G., Rustemoglu A., Karadag A., Sunguroglu A. Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population. Genet. Mol. Res. 2008, 7:1193-1199.
18. Hogg R.J., Portman R.J., Milliner D., Lemley K.V., Eddy A., Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000, 105:1242-1249.
19. Ieiri I., Takane H., Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. 2004, 43:553-576.
20. International Study of Kidney Disease in Children The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J. Pediatr. 1981, 98:561-564.
21. International Study of Kidney Disease in Children Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J. Pediatr. 1982, 101:514-518.
22. Jafar T., Prasad N., Agarwal V., Mahdi A., Gupta A., Sharma R.K., et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid resistant nephrotic syndrome in children. Nephrol. Dial. Transplant. 2011, 26(12):3968-3974.
23. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70:189-199.
24. Kim H.J., Hwang S.Y., Kim J.H., Park H.J., Lee S.G., Lee S.W., et al. Association between genetic polymorphism of multidrug resistance 1 gene and Sasang constitutions. Evid. Based Complement. Alternat. Med. 2009, 6(1):73-80.
25. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene. Science 2007, 315:525-528.
26. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83:2451-2458.
27. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481-494.
28. Kurzawski M., Pawlik A., Gornik W., Drozdzik M. Frequency of common MDR1 gene variants in a Polish population. Pharmacol. Rep. 2006, 58:35-40.
29. Kuwano M., Uchiumi T., Hayakawa H., Ono M., Wada M., Izumi H., Kohno K. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis related factors in human malignancies. Cancer Sci. 2003, 94:9-14.
30. Raghu G., Park S.W., Roninson I.B., Mechetner E.B. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp. Hematol. 1996, 24:1258-1264.
31. Richaud-Patin Y., Soto-Vega E., Jakez-Ocampo J., Llorente L. P-glycoprotein in autoimmune diseases. Autoimmun. Rev. 2004, 3:188-192.
32. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction?. Drug Metab. Pharmacokinet. 2005, 20:391-414.
33. Sakaeda T., Nakamura T., Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003, 4:397-410.
34. Sakaeda T., Nakamura T., Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Top. Med. Chem. 2004, 4:1385-1398.
35. Schwab M., Eichelbaum M., Fromm M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 2003, 43:285-307.
36. Siegsmund M., Brinkmann U., Scháffeler E., Weirich G., Schwab M., Eichelbaum M., et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 2002, 13:1847-1854.
37. Stachowski J., Zanker C.B., Runowski D., Zaniew M., Peszko A., Medyńska A., et al. Resistance to therapy in primary nephritic syndrome: effect of MDR1 gene activity. Pol. Merkur. Lek. 2000, 8:218-221.
38. Takane H., Kobayashi D., Hirota T., Kigawa J., Terakawa N., Otsubo K., et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 2004, 311:1179-1187.
39. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7735-7738.
40. Tsujimura S., Saito K., Nakayamada S., Nakano K., Tsukada J., Kohno K., et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 2004, 9:1265-1273.
41. Wasilewska A., Zalewski G., Chyczewski L., Zoch-Zwierz W. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephritic syndrome in children. Pediatr. Nephrol. 2007, 22:44-51.
42. Woodahl E.L., Ho R.J. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr. Drug Metab. 2004, 5:11-19.
43. Xu P., Jiang Z.P., Zhang B.K., Tu J.Y., Li H.D. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 2008, 82:221-227.
44. Youssef Doaa M., El-Shal Amal S. Multidrug resistance-1 gene polymorphisms in steroid resistance nephrotic syndrome with different pathology. Am. J. Med. Stud. 2013, 1(1):1-3.